AP vs REGN · rev $418.3M vs P/E 14, rev $14.34B
Ampco-Pittsburgh Corporation (AP) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Ampco-Pittsburgh Corporation (AP) is a metal fabrication company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported AP revenue for 2024-12-31 was $418.3M. Net income was $2.4M. Revenue was down 1.0% from 2023-12-31 to 2024-12-31. AP currently screens at market cap $221.2M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
AP currently screens at market cap $221.2M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the AP and REGN stock pages for the full models.
Not investment advice.